化学抗原受体T细胞治疗血液和固体恶性瘤的经济评估:系统性审查
Kednapa Thavorn1, Emily Rose Thompson2, Srishti Kumar2
1Clinical Epidemiology Program, Ottawa Hospital Research Institute, General Campus, Ottawa, ON, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada; Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
概括
化学抗原受体T细胞 (CAR-T) 疗法提供了更好的结果,但成本更高,成本效益不确定. 需要进一步的研究来澄清这些先进的癌症治疗方法的价值.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法代表了癌症治疗的重大进展.
- 对医疗保健系统来说,评估新型高成本疗法的经济价值至关重要.
- 本次审查重点关注各种癌症类型中CAR-T疗法的成本效益.
结论:
- 与标准治疗相比,CAR-T疗法与更高的成本和更好的质量调整寿命年 (QALYs) 有关.
- CAR-T疗法的成本效益是不确定的,并且高度依赖于患者群体,癌症类型和基本模型假设.
- 需要更精细的经济评估和持续的研究,以确定CAR-T疗法的价值在不同的瘤环境中.
更多相关视频
09:12Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
892
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
